Exact Mass: 299.2361

Exact Mass Matches: 299.2361

Found 244 metabolites which its exact mass value is equals to given mass value 299.2361, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Sphingosine

D-(+)-Erythro-1,3-dihydroxy-2-amino-4-trans-octadecene

C18H37NO2 (299.2824)


Sphingosine, also known as (4E)-sphingenine or sphing-4-enine, belongs to the class of organic compounds known as 1,2-aminoalcohols. These are organic compounds containing an alkyl chain with an amine group bound to the C1 atom and an alcohol group bound to the C2 atom. Sphingosine is an 18-carbon amino alcohol with an unsaturated hydrocarbon chain, which forms a primary part of sphingolipids. Sphingolipids are a class of cell membrane lipids that include sphingomyelin. Thus, sphingosine is considered to be a sphingoid base lipid. Sphingosine is a very hydrophobic molecule, practically insoluble (in water), and relatively neutral. Sphingosine is found in all living organisms ranging from bacteria to plants to humans. Sphingosine is synthesized from palmitoyl CoA and serine in a condensation required to yield dehydrosphingosine. Dehydrosphingosine is then reduced by NADPH to dihydrosphingosine (sphinganine), and finally oxidized by FAD to sphingosine. Within humans and other mammals, sphingosine participates in a number of enzymatic reactions. In particular, sphingosine can be converted into sphingosine 1-phosphate through its interaction with the enzyme sphingosine kinase 2. sphingosine 1-phosphate is an important signaling molecule. In addition, sphingosine can be biosynthesized from sphingosine 1-phosphate; which is mediated by the enzyme sphingosine-1-phosphate phosphatase 2. Sphingosine and its derivative sphinganine are the major bases of the sphingolipids in mammals. In humans, sphingosine is involved in globoid cell leukodystrophy. Cerebrosides is the common name for a group of glycosphingolipids called monoglycosylceramides which are important components in animal muscle and nerve cell membranes. They consist of a ceramide with a single sugar residue at the 1-hydroxyl moiety. The sugar residue can be either glucose or galactose; the two major types are therefore called glucocerebrosides and galactocerebrosides. Galactocerebrosides are typically found in neural tissue, while glucocerebrosides are found in other tissues. Sphingosine. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=123-78-4 (retrieved 2024-07-16) (CAS RN: 123-78-4). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0). D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator[1][2][3][4]. D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator[1][2][3][4].

   

Palmitoylethanolamide

N-(2-hydroxyethyl)hexadecanamide

C18H37NO2 (299.2824)


N-Palmitoylethanolamide (PEA) is present in the tissues of most mammals. It was initially described as an agonist of the type 2 cannabinoid receptor (CB2), although it is now universally recognized that PEA is in fact incapable of binding to cannabinoid receptors, or at least not to the known receptors. In addition to its anti-inflammatory activity, PEA also produces analgesia, neuroprotection, and possesses anti-epileptic properties. It also reduces gastrointestinal motility and cancer cell proliferation, as well as protecting the vascular endothelium in the ischemic heart. The physiological stimuli that regulate PEA levels in mammalian tissues are largely unknown, however, multiple studies indicate that this lipid accumulates during cellular stress, particularly following tissue injury. For example, PEA increases post-mortem in the pig brain. Similar elevations in PEA levels have been observed in the ischemic brain and PEA is also up-regulated in response to ultraviolet-B irradiation in mouse epidermal cells. Adipose tissue is highly implicated in the systemic secretion of IL-6 and leptin, and human mature adipocytes are able to secrete large quantity of PEA. Human adipose tissue can be subjected to modulation of its inflammatory state by lipopolysaccharide (LPS). LPS strongly inhibits adipose cell leptin release, with PEA acting as a potentiator of this inhibitory effect. These actions are not linked to a reduction in leptin gene transcription. Thus, PEA does not have an anti-inflammatory role in the secretion of IL-6 via NFkappaB at the adipocyte level, but instead seems to act at the heart of the LPS-stimulated pathway, which, independently of NFkappaB, inhibits the secretion of leptin. (PMID: 16884908). D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D063385 - Cannabinoid Receptor Modulators D018377 - Neurotransmitter Agents > D063385 - Cannabinoid Receptor Modulators > D063386 - Cannabinoid Receptor Agonists Isolated from soybean lecithin, egg yolk and peanut meal. Palmidrol is found in eggs, pulses, and nuts. C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000890 - Anti-Infective Agents > D000998 - Antiviral Agents D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents Same as: D08328 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Palmitoylethanolamide (Palmidrol) is an active endogenous compound which can used for preventing virus infection of the respiratory tract.

   

3-Dehydrosphinganine

(+-)-Isomer OF ketodihydrosphingosine

C18H37NO2 (299.2824)


3-Dehydrosphinganine is an intermediate in the metabolism of Glycosphingolipids. It is a substrate for Serine palmitoyltransferase 1 and Serine palmitoyltransferase 2. [HMDB]. 3-Dehydrosphinganine is found in many foods, some of which are beech nut, muskmelon, broccoli, and groundcherry. 3-Dehydrosphinganine is an intermediate in the metabolism of Glycosphingolipids. It is a substrate for Serine palmitoyltransferase 1 and Serine palmitoyltransferase 2.

   

Ethylketocyclazocine

Ethylketocyclazocine

C19H25NO2 (299.1885)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics

   

2-Undecyl-4(1H)-quinolinone

2-undecyl-1,4-dihydroquinolin-4-one

C20H29NO (299.2249)


2-Undecyl-4(1H)-quinolinone is found in herbs and spices. 2-Undecyl-4(1H)-quinolinone is an alkaloid from and roots of Ruta graveolens (rue) (as the main component of an inseparable mixture of 2-alkylquinolones contg. the 2-dodecyl, 2-tridecyl and 2-tetradecyl homologues) (Rutaceae). Alkaloid from and roots of Ruta graveolens (rue) (as the main component of an inseparable mixture of 2-alkylquinolones contg. the 2-dodecyl, 2-tridecyl and 2-tetradecyl homologues) (Rutaceae). 2-Undecyl-4(1H)-quinolinone is found in herbs and spices.

   

Pentadecanoylglycine

2-[(1-Hydroxypentadecylidene)amino]acetate

C17H33NO3 (299.246)


Pentadecanoylglycine is an acylglycine with C-15 fatty acid group as the acyl moiety. Acylglycines 1 possess a common amidoacetic acid moiety and are normally minor metabolites of fatty acids. Elevated levels of certain acylglycines appear in the urine and blood of patients with various fatty acid oxidation disorders. They are normally produced through the action of glycine N-acyltransferase which is an enzyme that catalyzes the chemical reaction: acyl-CoA + glycine ↔ CoA + N-acylglycine. Pentadecanoylglycine is an acylglycine with C-15 fatty acid group as the acyl moiety.

   

(2Z)-Non-2-enoylcarnitine

3-(Non-2-enoyloxy)-4-(trimethylazaniumyl)butanoic acid

C16H29NO4 (299.2096)


(2Z)-non-2-enoylcarnitine is an acylcarnitine. More specifically, it is an (2Z)-non-2-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2Z)-non-2-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2Z)-non-2-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Non-4-enoylcarnitine

3-(non-4-enoyloxy)-4-(trimethylazaniumyl)butanoate

C16H29NO4 (299.2096)


Non-4-enoylcarnitine is an acylcarnitine. More specifically, it is an non-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. non-4-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine non-4-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Non-5-enoylcarnitine

3-(non-5-enoyloxy)-4-(trimethylazaniumyl)butanoate

C16H29NO4 (299.2096)


Non-5-enoylcarnitine is an acylcarnitine. More specifically, it is an non-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. non-5-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine non-5-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Non-3-enoylcarnitine

3-(Non-3-enoyloxy)-4-(trimethylazaniumyl)butanoic acid

C16H29NO4 (299.2096)


Non-3-enoylcarnitine is an acylcarnitine. More specifically, it is an non-3-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. non-3-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine non-3-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Non-7-enoylcarnitine

3-(non-7-enoyloxy)-4-(trimethylazaniumyl)butanoate

C16H29NO4 (299.2096)


Non-7-enoylcarnitine is an acylcarnitine. More specifically, it is an non-7-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. non-7-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine non-7-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Non-6-enoylcarnitine

3-(Non-6-enoyloxy)-4-(trimethylazaniumyl)butanoic acid

C16H29NO4 (299.2096)


Non-6-enoylcarnitine is an acylcarnitine. More specifically, it is an non-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. non-6-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine non-6-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Lauroyl Valine

2-dodecanamido-3-methylbutanoic acid

C17H33NO3 (299.246)


N-lauroyl valine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Lauric acid amide of Valine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Lauroyl Valine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Lauroyl Valine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Myristoyl Alanine

2-tetradecanamidopropanoic acid

C17H33NO3 (299.246)


N-myristoyl alanine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Myristic acid amide of Alanine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Myristoyl Alanine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Myristoyl Alanine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

(+/-)-Ethylketocyclazocine

10-(cyclopropylmethyl)-1-ethyl-4-hydroxy-13-methyl-10-azatricyclo[7.3.1.0^{2,7}]trideca-2(7),3,5-trien-8-one

C19H25NO2 (299.1885)


   

(1R,9S)-10-(Cyclopropylmethyl)-12-ethyl-4-hydroxy-13-methyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-8-one

(1R,9S)-10-(Cyclopropylmethyl)-12-ethyl-4-hydroxy-13-methyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-8-one

C19H25NO2 (299.1885)


   

L-Threo-Sphingosine C-18

2-Aminooctadec-4-ene-1,3-diols

C18H37NO2 (299.2824)


   

Benz(cd)indole-6-carboxamide, 4-(dipropylamino)-1,3,4,5-tetrahydro-

6-(dipropylamino)-2-azatricyclo[6.3.1.0^{4,12}]dodeca-1(12),3,8,10-tetraene-9-carboxamide

C18H25N3O (299.1998)


   

3,7-Dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide

3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide

C20H29NO (299.2249)


   

3-Pyridinemethanol, 6-amino-alpha-(((1-methyl-4-phenylbutyl)amino)methyl)-

3-Pyridinemethanol, 6-amino-alpha-(((1-methyl-4-phenylbutyl)amino)methyl)-

C18H25N3O (299.1998)


   

Nylidrin

4-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]propyl}phenol

C19H25NO2 (299.1885)


G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CA - Sympathomimetics, labour repressants C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators > C04AA - 2-amino-1-phenylethanol derivatives D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

   

Palmitoylethanolamine

1-amino-2-hydroxyoctadecan-3-one

C18H37NO2 (299.2824)


   

2-(Nonan-8-one)-4-methoxy-quinoline

2-(Nonan-8-one)-4-methoxy-quinoline

C19H25NO2 (299.1885)


   

DTXSID10707391

DTXSID10707391

C19H25NO2 (299.1885)


   
   

ATISINE, AZOMETHINE

ATISINE, AZOMETHINE

C20H29NO (299.2249)


   

Dehydroabietamide

Dehydroabietamide

C20H29NO (299.2249)


   

N-(3-Hydroxydodecanoyl)-DL-homoserine lactone

N-(3-Hydroxydodecanoyl)-DL-homoserine lactone

C16H29NO4 (299.2096)


   

nylidrin

nylidrin

C19H25NO2 (299.1885)


G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CA - Sympathomimetics, labour repressants C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators > C04AA - 2-amino-1-phenylethanol derivatives D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents CONFIDENCE standard compound; INTERNAL_ID 6; HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu) INTERNAL_ID 6; CONFIDENCE standard compound; HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu) CONFIDENCE Reference Standard (Level 1); HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu); Flow Injection CONFIDENCE Reference Standard (Level 1); HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu)

   

Haminol C|Haminol-C

Haminol C|Haminol-C

C19H25NO2 (299.1885)


   

mirabilin I

mirabilin I

C19H29N3 (299.2361)


   

(+-)-7,8,9-trimethyl-eleocarpine|(+-)-Elaeocarpin|6a,11,12a,12b-tetramethyl-(6ar,12at,12bc)-1,2,3,5,6,6a,12a,12b-octahydro-chromeno[2,3-g]indolizin-12-one

(+-)-7,8,9-trimethyl-eleocarpine|(+-)-Elaeocarpin|6a,11,12a,12b-tetramethyl-(6ar,12at,12bc)-1,2,3,5,6,6a,12a,12b-octahydro-chromeno[2,3-g]indolizin-12-one

C19H25NO2 (299.1885)


   

(3S*,4R*,7S*,8S*,11S*,13R*)-8-isocyano-1(12)-cycloamphilectene

(3S*,4R*,7S*,8S*,11S*,13R*)-8-isocyano-1(12)-cycloamphilectene

C21H33N (299.2613)


   

tetradeca-2t,6t,8t-12c-tetraen-10-ynoic isobutyl amide

tetradeca-2t,6t,8t-12c-tetraen-10-ynoic isobutyl amide

C20H29NO (299.2249)


   

(1S*,3S*,4R*,7S*,8R*,13R*)-7-isocyano-11-cycloamphilectene

(1S*,3S*,4R*,7S*,8R*,13R*)-7-isocyano-11-cycloamphilectene

C21H33N (299.2613)


   

3,4-Dihydro,1-hydroxy-Dictyolomide A|dictylomide B

3,4-Dihydro,1-hydroxy-Dictyolomide A|dictylomide B

C19H25NO2 (299.1885)


   

iso-6-canavaline|iso-6-Carnavalin

iso-6-canavaline|iso-6-Carnavalin

C18H37NO2 (299.2824)


   
   

2-AMINOOCTADEC-8-ENE-1,3-DIOL

2-AMINOOCTADEC-8-ENE-1,3-DIOL

C18H37NO2 (299.2824)


   

Veatchine azomethine

Veatchine azomethine

C20H29NO (299.2249)


   

(-)-Prosafrine

(-)-Prosafrine

C18H37NO2 (299.2824)


   

Me ester,(E)-oxime-2-Oxo-hexadecanoic acid

Me ester,(E)-oxime-2-Oxo-hexadecanoic acid

C17H33NO3 (299.246)


   

(2E,6E,8E)-2,6,8-Hexadecatrien-10-insaeure-pyrrolidid

(2E,6E,8E)-2,6,8-Hexadecatrien-10-insaeure-pyrrolidid

C20H29NO (299.2249)


   

hexadeca-9Z-en-10-ynoic acid pyrrolide

hexadeca-9Z-en-10-ynoic acid pyrrolide

C20H29NO (299.2249)


   

(1S*,3S*,4R*,7S*,12S*,13S*)-8-isocyano-10,14-amphilectadiene

(1S*,3S*,4R*,7S*,12S*,13S*)-8-isocyano-10,14-amphilectadiene

C21H33N (299.2613)


   

SCHEMBL7125067

SCHEMBL7125067

C18H37NO2 (299.2824)


   

(2S,3S,6E)-N,N-dimethyl-2-[(R)-methylsulfinyl]tetradeca-6,13-dien-3-amine|(2S,3S,6E)-N,N-dimethyl-2-[(S)-methylsulfinyl]tetradeca-6,13-dien-3-amine|aplisulfamine A|aplisulfamine B

(2S,3S,6E)-N,N-dimethyl-2-[(R)-methylsulfinyl]tetradeca-6,13-dien-3-amine|(2S,3S,6E)-N,N-dimethyl-2-[(S)-methylsulfinyl]tetradeca-6,13-dien-3-amine|aplisulfamine A|aplisulfamine B

C17H33NOS (299.2283)


   
   

(3R,5S)-3-methyl-5-((5E)-pentadec-5-ene-7,9-diynyl)-pyrrolidin-2-one

(3R,5S)-3-methyl-5-((5E)-pentadec-5-ene-7,9-diynyl)-pyrrolidin-2-one

C20H29NO (299.2249)


   

1-Methyl-2-decylquinoline-4(1H)-one

1-Methyl-2-decylquinoline-4(1H)-one

C20H29NO (299.2249)


   

7-isocyanoisoneoamphilecta-1(14),15-diene

7-isocyanoisoneoamphilecta-1(14),15-diene

C21H33N (299.2613)


   

2-Methylpropylamide-(2E,9Z)-2,9-Hexadecadiene-12,14-diynoic acid|hexadeca-2E,9Z-dien-12,14-diynoic acid isobutylamide

2-Methylpropylamide-(2E,9Z)-2,9-Hexadecadiene-12,14-diynoic acid|hexadeca-2E,9Z-dien-12,14-diynoic acid isobutylamide

C20H29NO (299.2249)


   

Haminol 6|Haminol-6

Haminol 6|Haminol-6

C19H25NO2 (299.1885)


   

1-Methyl-2-(8-oxononyl)quinoline-4(1H)-one

1-Methyl-2-(8-oxononyl)quinoline-4(1H)-one

C19H25NO2 (299.1885)


   

Haminol 2|haminol acetate|Haminol-2

Haminol 2|haminol acetate|Haminol-2

C19H25NO2 (299.1885)


   

N-[2-(2,2-Dimethyl-2H-1-benzopyran-6-yl)ethyl]-N-methyl-3-methyl-2-butenamide

N-[2-(2,2-Dimethyl-2H-1-benzopyran-6-yl)ethyl]-N-methyl-3-methyl-2-butenamide

C19H25NO2 (299.1885)


   

5-hydroxy-6-methyl-2-piperidinedodecanol

5-hydroxy-6-methyl-2-piperidinedodecanol

C18H37NO2 (299.2824)


   

Trachelanthamidine 2S-hydroxy-2S-(1S-hydroxyethyl)-4-methylpentanoyl ester

Trachelanthamidine 2S-hydroxy-2S-(1S-hydroxyethyl)-4-methylpentanoyl ester

C16H29NO4 (299.2096)


   

(2E,7Z)-2,7-Hexadecadien-10-insaeure-(2,3-didehydropyrrolidid)|(2E,7Z)-2,7-Hexadecadien-10-insaeure-<2,3-didehydropyrrolidid>

(2E,7Z)-2,7-Hexadecadien-10-insaeure-(2,3-didehydropyrrolidid)|(2E,7Z)-2,7-Hexadecadien-10-insaeure-<2,3-didehydropyrrolidid>

C20H29NO (299.2249)


   

Leptophyllin B

Leptophyllin B

C17H33NO3 (299.246)


   

Viridiflorine

Viridiflorine

C16H29NO4 (299.2096)


   

Haminol B|Haminol-B

Haminol B|Haminol-B

C19H25NO2 (299.1885)


   

glaciapyrrole C

glaciapyrrole C

C19H25NO2 (299.1885)


   

DErySphingosine

DErySphingosine

C18H37NO2 (299.2824)


Acquisition and generation of the data is financially supported by the Max-Planck-Society

   

MLS001332469-01!D-Sphingosine123-78-4

MLS001332469-01!D-Sphingosine123-78-4

C18H37NO2 (299.2824)


   

UHQ (mixed MS2 C11:db:UHQ)

UHQ (mixed MS2 C11:db:UHQ)

C20H29NO (299.2249)


   

Sphingosine

2R-aminooctadec-4Z-ene-1,3S-diol

C18H37NO2 (299.2824)


A sphing-4-enine in which the double bond is trans. D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator[1][2][3][4]. D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator[1][2][3][4].

   

Palmitoyl ethanolamide

Palmitoyl ethanolamide

C18H37NO2 (299.2824)


An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.

   

NAE 16:0

N-hexadecanoyl-ethanolamine

C18H37NO2 (299.2824)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D063385 - Cannabinoid Receptor Modulators D018377 - Neurotransmitter Agents > D063385 - Cannabinoid Receptor Modulators > D063386 - Cannabinoid Receptor Agonists C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000890 - Anti-Infective Agents > D000998 - Antiviral Agents CONFIDENCE standard compound; INTERNAL_ID 42 D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Palmitoylethanolamide (Palmidrol) is an active endogenous compound which can used for preventing virus infection of the respiratory tract.

   

3-hydroxy-C12 homoserine lactone

3-Hydroxy-N-(2-oxotetrahydrofuran-3-yl)dodecanamide

C16H29NO4 (299.2096)


CONFIDENCE standard compound; INTERNAL_ID 217

   

nonylphenazolone

nonylphenazolone

C19H25NO2 (299.1885)


   

D-Sphingosine

D-Sphingosine

C18H37NO2 (299.2824)


   

C18_Sphingosine

D-erythro-Sphingosine

C18H37NO2 (299.2824)


D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator[1][2][3][4]. D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator[1][2][3][4].

   

L-threo-Sphingosine C-18

(2S,3S,4E)-2-Amino-4-octadecene-1,3-diol

C18H37NO2 (299.2824)


   

Palmitoyl-EA(d4)

N-(Hexadecanoyl)-ethanolamine(d4)

C18H37NO2 (299.2824)


   

5-hydroxy,3E-sphingosine

2R-amino-3E-octadecene-1,5-diol

C18H37NO2 (299.2824)


   

Sphing-8Z-enine

(8Z,d18:1) sphingosine

C18H37NO2 (299.2824)


   

12-amino-octadecanoic acid

12-amino-octadecanoic acid

C18H37NO2 (299.2824)


   

2-amino-octadecanoic acid

2-amino-octadecanoic acid

C18H37NO2 (299.2824)


   

Palmitoyl-EA

N-hexadecanoyl-ethanolamine

C18H37NO2 (299.2824)


   

4-Hydroxy-2-undecylquinoline

2-undecyl-1,4-dihydroquinolin-4-one

C20H29NO (299.2249)


   

3OH-C12-HSL

N-(3-hydroxy-dodecanoyl)-homoserine lactone

C16H29NO4 (299.2096)


   

SPB 18:1;O2

2R-amino-3E-octadecene-1,5-diol

C18H37NO2 (299.2824)


   

CIS-6,9,12,15-OCTADECATETRAENOIC ACID*SO DIUM

CIS-6,9,12,15-OCTADECATETRAENOIC ACID*SO DIUM

C18H28NaO2 (299.1987)


   
   

4-Cyanophenyl trans-4-pentylcyclohexanecarboxylate

4-Cyanophenyl trans-4-pentylcyclohexanecarboxylate

C19H25NO2 (299.1885)


   

AMMONIUM OLEATE

AMMONIUM OLEATE

C18H37NO2 (299.2824)


   

Propinetidine

Propinetidine

C19H25NO2 (299.1885)


   
   
   

2-(dimethylamino)ethyl 2-methylprop-2-enoate,2-methylpropyl 2-methylprop-2-enoate

2-(dimethylamino)ethyl 2-methylprop-2-enoate,2-methylpropyl 2-methylprop-2-enoate

C16H29NO4 (299.2096)


   

1-BOC-3-(3-MORPHOLIN-4-YL-PROPYLAMINO)-AZETIDINE

1-BOC-3-(3-MORPHOLIN-4-YL-PROPYLAMINO)-AZETIDINE

C15H29N3O3 (299.2209)


   
   

N-(1-oxotetradecyl)sarcosine

N-(1-oxotetradecyl)sarcosine

C17H33NO3 (299.246)


   

1-benzyl-1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester

1-benzyl-1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester

C18H26BNO2 (299.2056)


   

1-Benzyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine

1-Benzyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine

C18H26BNO2 (299.2056)


   

(S)-[1-([1,4]DIAZEPANE-1-CARBONYL)-2-METHYL-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER

(S)-[1-([1,4]DIAZEPANE-1-CARBONYL)-2-METHYL-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER

C15H29N3O3 (299.2209)


   

3-Ethyl 1-(2-methyl-2-propanyl) 3-isopropyl-1,3-piperidinedicarbo xylate

3-Ethyl 1-(2-methyl-2-propanyl) 3-isopropyl-1,3-piperidinedicarbo xylate

C16H29NO4 (299.2096)


   

Butyl 2-methyl-2-propenoate, N-[(2-methylpropoxy)methyl]-2-propenamide polymer

Butyl 2-methyl-2-propenoate, N-[(2-methylpropoxy)methyl]-2-propenamide polymer

C16H29NO4 (299.2096)


   

12-HYDROXYSTEARAMIDE

12-HYDROXYSTEARAMIDE

C18H37NO2 (299.2824)


   

(carboxylatomethyl)dimethyltetradecylammonium

(carboxylatomethyl)dimethyltetradecylammonium

C18H37NO2 (299.2824)


   

3,3-DIMETHOXY-ALPHA-METHYLDIPHENETHYLAMINE HYDROCHLORIDE

3,3-DIMETHOXY-ALPHA-METHYLDIPHENETHYLAMINE HYDROCHLORIDE

C19H25NO2 (299.1885)


   

(S)-ethyl 2-(tert-butoxycarbonylamino)non-8-enoate

(S)-ethyl 2-(tert-butoxycarbonylamino)non-8-enoate

C16H29NO4 (299.2096)


   

N-Tetradecanoyl-L-alanine

N-Tetradecanoyl-L-alanine

C17H33NO3 (299.246)


   

N-Dodecanoyl-L-valine

N-Dodecanoyl-L-valine

C17H33NO3 (299.246)


   

Ethyl 1-Boc-4-iso-propyl-4-piperidinecarboxylate

Ethyl 1-Boc-4-iso-propyl-4-piperidinecarboxylate

C16H29NO4 (299.2096)


   
   

6-[4-[2-(dimethylamino)ethyl]-5-ethyl-2-methoxyphenyl]pyridin-2-amine

6-[4-[2-(dimethylamino)ethyl]-5-ethyl-2-methoxyphenyl]pyridin-2-amine

C18H25N3O (299.1998)


   

7-(5-Ethyl-2-nonanyl)-8-quinolinol

7-(5-Ethyl-2-nonanyl)-8-quinolinol

C20H29NO (299.2249)


   

3-HYDROXY-N-((S)-2-OXOTETRAHYDROFURAN-3-YL)DODECANAMIDE

3-HYDROXY-N-((S)-2-OXOTETRAHYDROFURAN-3-YL)DODECANAMIDE

C16H29NO4 (299.2096)


   

2-aminooctadec-4-ene-1,3-diol

2-aminooctadec-4-ene-1,3-diol

C18H37NO2 (299.2824)


   

Retinamide

Retinamide

C20H29NO (299.2249)


D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids D000970 - Antineoplastic Agents

   

3-Cyclopropylmethyl-5-ethyl-8-hydroxy-11-methyl-3,4,5,6-tetrahydro-2H-2,6-methano-benzo[d]azocin-1-one

3-Cyclopropylmethyl-5-ethyl-8-hydroxy-11-methyl-3,4,5,6-tetrahydro-2H-2,6-methano-benzo[d]azocin-1-one

C19H25NO2 (299.1885)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics

   

4-(Dipropylamino)-1,3,4,5-tetrahydrobenz(cd)indole-6-carboxamide

4-(Dipropylamino)-1,3,4,5-tetrahydrobenz(cd)indole-6-carboxamide

C18H25N3O (299.1998)


   

L-threo-Sphingosine

(2S,3S,4E)-2-Amino-4-octadecene-1,3-diol

C18H37NO2 (299.2824)


   

L-erythro-Sphingosine

L-erythro-Sphingosine

C18H37NO2 (299.2824)


   

12-Aminooctadecanoic acid

12-Aminooctadecanoic acid

C18H37NO2 (299.2824)


   

1-Cyclohexyl-3-[(1,2-dimethyl-5-indolyl)methyl]urea

1-Cyclohexyl-3-[(1,2-dimethyl-5-indolyl)methyl]urea

C18H25N3O (299.1998)


   

N,N-diethyl-2-(4-methyl-1-piperazinyl)-4-quinazolinamine

N,N-diethyl-2-(4-methyl-1-piperazinyl)-4-quinazolinamine

C17H25N5 (299.211)


   

2-(beta-Dimethylaminopropionyl)-5,7-dimethyl-1,2,3,4-tetrahydropyrimido(3,4-a)indole

2-(beta-Dimethylaminopropionyl)-5,7-dimethyl-1,2,3,4-tetrahydropyrimido(3,4-a)indole

C18H25N3O (299.1998)


   

all-trans-Retinoate

all-trans-Retinoate

C20H27O2- (299.2011)


A retinoate that is the conjugate base of all-trans-retinoic acid.

   

18-Hydroxystearate

18-Hydroxystearate

C18H35O3- (299.2586)


An omega-hydroxy fatty acid anion that is the conjugate base of 18-hydroxystearic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoate

3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoate

C20H27O2- (299.2011)


COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

(S)-2-Hydroxystearate

(S)-2-Hydroxystearate

C18H35O3- (299.2586)


   

(R)-10-Hydroxystearate

(R)-10-Hydroxystearate

C18H35O3- (299.2586)


   

9-Hydroxystearate

9-Hydroxystearate

C18H35O3- (299.2586)


   

13-cis-Retinoate

13-cis-Retinoate

C20H27O2- (299.2011)


   

(R)-2-Hydroxystearate

(R)-2-Hydroxystearate

C18H35O3- (299.2586)


   
   

(1R,4aS)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylate

(1R,4aS)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylate

C20H27O2- (299.2011)


   

(2S,3R)-2-aminooctadec-8-ene-1,3-diol

(2S,3R)-2-aminooctadec-8-ene-1,3-diol

C18H37NO2 (299.2824)


   

(2Z,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate

(2Z,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate

C20H27O2- (299.2011)


   

Non-4-enoylcarnitine

Non-4-enoylcarnitine

C16H29NO4 (299.2096)


   

Non-5-enoylcarnitine

Non-5-enoylcarnitine

C16H29NO4 (299.2096)


   

Non-3-enoylcarnitine

Non-3-enoylcarnitine

C16H29NO4 (299.2096)


   

Non-7-enoylcarnitine

Non-7-enoylcarnitine

C16H29NO4 (299.2096)


   

Non-6-enoylcarnitine

Non-6-enoylcarnitine

C16H29NO4 (299.2096)


   

(2Z)-Non-2-enoylcarnitine

(2Z)-Non-2-enoylcarnitine

C16H29NO4 (299.2096)


   

9-cis-Retinoate

9-cis-Retinoate

C20H27O2- (299.2011)


A retinoate that is the conjugate base of 9-cis-retinoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

2-hydroxystearate

2-hydroxystearate

C18H35O3- (299.2586)


   

cis-Sphingosine

cis-Sphingosine

C18H37NO2 (299.2824)


   

3-Hydroxyoctadecanoate

3-Hydroxyoctadecanoate

C18H35O3- (299.2586)


   

12-Hydroxyoctadecanoate

12-Hydroxyoctadecanoate

C18H35O3- (299.2586)


A hydroxy saturated fatty acid anion that is the conjugate base of 12-hydroxyoctadecanoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

11-cis-Retinoate

11-cis-Retinoate

C20H27O2- (299.2011)


A retinoate that is the conjugate base of 11-cis-retinoic acid, obtaained by deprotonation of the carboxy group; major species at pH 7.3.

   

(2R,3S,4Z)-2-aminooctadec-4-ene-1,3-diol

(2R,3S,4Z)-2-aminooctadec-4-ene-1,3-diol

C18H37NO2 (299.2824)


   

(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylate

(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylate

C20H27O2- (299.2011)


   

5-Hydroxyoctadecanoate

5-Hydroxyoctadecanoate

C18H35O3- (299.2586)


   

10-Hydroxyoctadecanoate

10-Hydroxyoctadecanoate

C18H35O3- (299.2586)


A hydroxy saturated fatty acid anion resulting from the deprotonation of the carboxy group of 10-hydroxyoctadecanoic acid.

   

13-Hydroxyoctadecanoate

13-Hydroxyoctadecanoate

C18H35O3- (299.2586)


   

(5S)-1-(4-cyclohexylbutyl)-5-phenyl-4,5-dihydroimidazol-2-amine

(5S)-1-(4-cyclohexylbutyl)-5-phenyl-4,5-dihydroimidazol-2-amine

C19H29N3 (299.2361)


   

N-(1-butyl-2-benzimidazolyl)cyclohexanecarboxamide

N-(1-butyl-2-benzimidazolyl)cyclohexanecarboxamide

C18H25N3O (299.1998)


   

1-[2-(diethylamino)ethyl]-5,6-dimethyl-1H-pyrrolo[1,2,3-de]quinoxalin-2(3H)-one

1-[2-(diethylamino)ethyl]-5,6-dimethyl-1H-pyrrolo[1,2,3-de]quinoxalin-2(3H)-one

C18H25N3O (299.1998)


   

(E)-Delta-methoxymycolate

(E)-Delta-methoxymycolate

C17H31O4- (299.2222)


   

2,6-Ditert-butyl-4-(4-methoxyphenyl)pyrylium

2,6-Ditert-butyl-4-(4-methoxyphenyl)pyrylium

C20H27O2+ (299.2011)


   

N-[(E)-1,3-dihydroxypentadec-4-en-2-yl]acetamide

N-[(E)-1,3-dihydroxypentadec-4-en-2-yl]acetamide

C17H33NO3 (299.246)


   

N-[(E)-1,3-dihydroxyoct-4-en-2-yl]nonanamide

N-[(E)-1,3-dihydroxyoct-4-en-2-yl]nonanamide

C17H33NO3 (299.246)


   

N-[(E)-1,3-dihydroxynon-4-en-2-yl]octanamide

N-[(E)-1,3-dihydroxynon-4-en-2-yl]octanamide

C17H33NO3 (299.246)


   

N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]propanamide

N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]propanamide

C17H33NO3 (299.246)


   

N-[(E)-1,3-dihydroxytridec-4-en-2-yl]butanamide

N-[(E)-1,3-dihydroxytridec-4-en-2-yl]butanamide

C17H33NO3 (299.246)


   

N-[(E)-1,3-dihydroxyundec-4-en-2-yl]hexanamide

N-[(E)-1,3-dihydroxyundec-4-en-2-yl]hexanamide

C17H33NO3 (299.246)


   

N-[(E)-1,3-dihydroxydec-4-en-2-yl]heptanamide

N-[(E)-1,3-dihydroxydec-4-en-2-yl]heptanamide

C17H33NO3 (299.246)


   

N-[(E)-1,3-dihydroxydodec-4-en-2-yl]pentanamide

N-[(E)-1,3-dihydroxydodec-4-en-2-yl]pentanamide

C17H33NO3 (299.246)


   

Propanoic acid, 2-[(1-cyclohexylethyl)carbamoyl]-, trimethylsilyl ester

Propanoic acid, 2-[(1-cyclohexylethyl)carbamoyl]-, trimethylsilyl ester

C15H29NO3Si (299.1917)


   

3-dehydrosphinganine

3-dehydrosphinganine

C18H37NO2 (299.2824)


A 2-amino-1-hydroxyoctadecan-3-one that has S-configuration.

   

CID 443409

CID 443409

C19H25NO2 (299.1885)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics

   

Palmidrol

N-hexadecanoyl-ethanolamine

C18H37NO2 (299.2824)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D063385 - Cannabinoid Receptor Modulators D018377 - Neurotransmitter Agents > D063385 - Cannabinoid Receptor Modulators > D063386 - Cannabinoid Receptor Agonists C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000890 - Anti-Infective Agents > D000998 - Antiviral Agents D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents Same as: D08328 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Palmitoylethanolamide (Palmidrol) is an active endogenous compound which can used for preventing virus infection of the respiratory tract.

   

(R)-10-hydroxyoctadecanoate

(R)-10-hydroxyoctadecanoate

C18H35O3 (299.2586)


A hydroxy monocarboxylic acid anion resulting from the removal of the proton from the carboxy group of (R)-10-hydroxyoctadecanoic acid.

   

2-Undecyl-4(1H)-quinolinone

2-Undecyl-4(1H)-quinolinone

C20H29NO (299.2249)


   

Pentadecanoylglycine

Pentadecanoylglycine

C17H33NO3 (299.246)


   

2-Hydroxyoctadecanoate

2-Hydroxyoctadecanoate

C18H35O3 (299.2586)


A 2-hydroxy fatty acid anion that is the conjugate base of 2-hydroxyoctadecanoic acid (stearic acid), obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

3-Hydroxy-N-(2-oxotetrahydrofuran-3-yl)dodecanamide

3-Hydroxy-N-(2-oxotetrahydrofuran-3-yl)dodecanamide

C16H29NO4 (299.2096)


   

2-amino-1-hydroxyoctadecan-3-one

2-amino-1-hydroxyoctadecan-3-one

C18H37NO2 (299.2824)


   

(8Z,d18:1) sphingosine

(8Z,d18:1) sphingosine

C18H37NO2 (299.2824)


   

Dehydroabietate

Dehydroabietate

C20H27O2 (299.2011)


A monocarboxylic acid anion that is the conjugate base of dehydroabietic acid, obtained by deprotonation of the carboxy group.

   

3-hydroxystearate

3-hydroxystearate

C18H35O3 (299.2586)


A 3-hydroxy fatty acid anion that is the conjugate base of 3-hydroxystearic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   
   

(R)-2-hydroxyoctadecanoate

(R)-2-hydroxyoctadecanoate

C18H35O3 (299.2586)


A 2-hydroxyoctadecanoate that has R configuration. The conjugate base of (R)-2-hydroxyoctadecanoic acid.

   

(S)-2-Hydroxyoctadecanoate

(S)-2-Hydroxyoctadecanoate

C18H35O3 (299.2586)


A 2-hydroxyoctadecanoate that has S configuration. The conjugate base of (S)-2-hydroxystearic acid obtained via deprotonation of the carboxy group; major species at pH 7.3.

   

Sphingosine (d18:1)

SPH(d18:1)

C18H37NO2 (299.2824)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

AEA(16:0)

AEA(16:0)

C18H37NO2 (299.2824)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

Sphingosine(d18:1)

Sphingosine(d18:1)

C18H37NO2 (299.2824)


PANOMIX internal lipid standards

   

NA-Ala 14:0

NA-Ala 14:0

C17H33NO3 (299.246)


   

NA-Gly 15:0

NA-Gly 15:0

C17H33NO3 (299.246)


   

NA-Ile 11:0

NA-Ile 11:0

C17H33NO3 (299.246)


   

NA-Leu 11:0

NA-Leu 11:0

C17H33NO3 (299.246)


   

NA-Val 12:0

NA-Val 12:0

C17H33NO3 (299.246)


   
   

Undecyl-(1H-quinolinone)

Undecyl-(1H-quinolinone)

C20H29NO (299.2249)


   

Ketosphinganine

Ketosphinganine

C18H37NO2 (299.2824)


   

(2r,3r,6r)-6-(11-hydroxydodecyl)-2-methylpiperidin-3-ol

(2r,3r,6r)-6-(11-hydroxydodecyl)-2-methylpiperidin-3-ol

C18H37NO2 (299.2824)


   

11-[(2r,5r,6r)-5-hydroxy-6-methylpiperidin-2-yl]undecanoic acid

11-[(2r,5r,6r)-5-hydroxy-6-methylpiperidin-2-yl]undecanoic acid

C17H33NO3 (299.246)


   

(2s,4e,6e,11e)-12-(pyridin-3-yl)dodeca-4,6,11-trien-2-yl acetate

(2s,4e,6e,11e)-12-(pyridin-3-yl)dodeca-4,6,11-trien-2-yl acetate

C19H25NO2 (299.1885)


   

2-decyl-1-methylquinolin-4-one

2-decyl-1-methylquinolin-4-one

C20H29NO (299.2249)


   

(2e,6e,8e)-1-(pyrrolidin-1-yl)hexadeca-2,6,8-trien-10-yn-1-one

(2e,6e,8e)-1-(pyrrolidin-1-yl)hexadeca-2,6,8-trien-10-yn-1-one

C20H29NO (299.2249)


   

(2e,6e,8e,12z)-n-(2-methylpropyl)hexadeca-2,6,8,12-tetraen-10-ynimidic acid

(2e,6e,8e,12z)-n-(2-methylpropyl)hexadeca-2,6,8,12-tetraen-10-ynimidic acid

C20H29NO (299.2249)


   

(2s,4e,6e,8e)-12-(pyridin-3-yl)dodeca-4,6,8-trien-2-yl acetate

(2s,4e,6e,8e)-12-(pyridin-3-yl)dodeca-4,6,8-trien-2-yl acetate

C19H25NO2 (299.1885)


   

(1s,10s,11s)-1,7,10,11-tetramethyl-2-oxa-15-azatetracyclo[8.7.0.0³,⁸.0¹¹,¹⁵]heptadeca-3(8),4,6-trien-9-one

(1s,10s,11s)-1,7,10,11-tetramethyl-2-oxa-15-azatetracyclo[8.7.0.0³,⁸.0¹¹,¹⁵]heptadeca-3(8),4,6-trien-9-one

C19H25NO2 (299.1885)


   

1,7,10,11-tetramethyl-2-oxa-15-azatetracyclo[8.7.0.0³,⁸.0¹¹,¹⁵]heptadeca-3(8),4,6-trien-9-one

1,7,10,11-tetramethyl-2-oxa-15-azatetracyclo[8.7.0.0³,⁸.0¹¹,¹⁵]heptadeca-3(8),4,6-trien-9-one

C19H25NO2 (299.1885)


   

2-(nonan-8-one)-4-methoxy-quinoline

NA

C19H25NO2 (299.1885)


{"Ingredient_id": "HBIN006130","Ingredient_name": "2-(nonan-8-one)-4-methoxy-quinoline","Alias": "NA","Ingredient_formula": "C19H25NO2","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "15680","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

2-(nonan-8-one)-n-methyl-4-quinolone

NA

C19H25NO2 (299.1885)


{"Ingredient_id": "HBIN006131","Ingredient_name": "2-(nonan-8-one)-n-methyl-4-quinolone","Alias": "NA","Ingredient_formula": "C19H25NO2","Ingredient_Smile": "CCCCCCC=CCC1=C(C(=O)C2=CC=CC=C2N1O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "15681","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-13-en-6-ol

11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-13-en-6-ol

C20H29NO (299.2249)


   

2-undecyl-3h-quinolin-4-one

2-undecyl-3h-quinolin-4-one

C20H29NO (299.2249)


   

6-(11-hydroxydodecyl)-2-methylpiperidin-3-ol

6-(11-hydroxydodecyl)-2-methylpiperidin-3-ol

C18H37NO2 (299.2824)


   

3-methyl-5-[3-methyl-3-(4-methylpent-3-en-1-yl)oxiran-2-yl]-1-(1h-pyrrol-2-yl)penta-2,4-dien-1-one

3-methyl-5-[3-methyl-3-(4-methylpent-3-en-1-yl)oxiran-2-yl]-1-(1h-pyrrol-2-yl)penta-2,4-dien-1-one

C19H25NO2 (299.1885)


   

(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2s,3s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylpentanoate

(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2s,3s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylpentanoate

C16H29NO4 (299.2096)


   

(2e,9z)-n-(2-methylpropyl)hexadeca-2,9-dien-12,14-diynimidic acid

(2e,9z)-n-(2-methylpropyl)hexadeca-2,9-dien-12,14-diynimidic acid

C20H29NO (299.2249)


   

(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2r,3s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylpentanoate

(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2r,3s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylpentanoate

C16H29NO4 (299.2096)


   

n-(2-methylpropyl)hexadeca-2,9-dien-12,14-diynimidic acid

n-(2-methylpropyl)hexadeca-2,9-dien-12,14-diynimidic acid

C20H29NO (299.2249)


   

6-(12-hydroxydodecyl)-2-methylpiperidin-3-ol

6-(12-hydroxydodecyl)-2-methylpiperidin-3-ol

C18H37NO2 (299.2824)


   

(1r,10s,11s)-1,7,10,11-tetramethyl-2-oxa-15-azatetracyclo[8.7.0.0³,⁸.0¹¹,¹⁵]heptadeca-3(8),4,6-trien-9-one

(1r,10s,11s)-1,7,10,11-tetramethyl-2-oxa-15-azatetracyclo[8.7.0.0³,⁸.0¹¹,¹⁵]heptadeca-3(8),4,6-trien-9-one

C19H25NO2 (299.1885)


   

(2e,4e,6e)-12-(pyridin-3-yl)dodeca-2,4,6-trien-1-yl acetate

(2e,4e,6e)-12-(pyridin-3-yl)dodeca-2,4,6-trien-1-yl acetate

C19H25NO2 (299.1885)


   

n-[2-(2,2-dimethylchromen-6-yl)ethyl]-n,3-dimethylbut-2-enamide

n-[2-(2,2-dimethylchromen-6-yl)ethyl]-n,3-dimethylbut-2-enamide

C19H25NO2 (299.1885)


   

12-(pyridin-3-yl)dodeca-4,6,8-trien-2-yl acetate

12-(pyridin-3-yl)dodeca-4,6,8-trien-2-yl acetate

C19H25NO2 (299.1885)


   

n-(2-methylpropyl)hexadeca-2,6,8,12-tetraen-10-ynimidic acid

n-(2-methylpropyl)hexadeca-2,6,8,12-tetraen-10-ynimidic acid

C20H29NO (299.2249)


   

(1s,2s,4s,6r,7s,10r,11r)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-13-en-6-ol

(1s,2s,4s,6r,7s,10r,11r)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-13-en-6-ol

C20H29NO (299.2249)


   

(2s,3s,6r)-6-(12-hydroxydodecyl)-2-methylpiperidin-3-ol

(2s,3s,6r)-6-(12-hydroxydodecyl)-2-methylpiperidin-3-ol

C18H37NO2 (299.2824)


   

(2e,6z,8e,12z)-n-(2-methylpropyl)hexadeca-2,6,8,12-tetraen-10-ynimidic acid

(2e,6z,8e,12z)-n-(2-methylpropyl)hexadeca-2,6,8,12-tetraen-10-ynimidic acid

C20H29NO (299.2249)


   

(2r,3r,6s)-6-(11-hydroxydodecyl)-2-methylpiperidin-3-ol

(2r,3r,6s)-6-(11-hydroxydodecyl)-2-methylpiperidin-3-ol

C18H37NO2 (299.2824)


   

(2z,6z,8z,12e)-n-(2-methylpropyl)hexadeca-2,6,8,12-tetraen-10-ynimidic acid

(2z,6z,8z,12e)-n-(2-methylpropyl)hexadeca-2,6,8,12-tetraen-10-ynimidic acid

C20H29NO (299.2249)


   

(1s,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2r,3s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylpentanoate

(1s,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2r,3s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylpentanoate

C16H29NO4 (299.2096)


   

9-(4-methoxyquinolin-2-yl)nonan-2-one

9-(4-methoxyquinolin-2-yl)nonan-2-one

C19H25NO2 (299.1885)


   

(2s,5e,8e,10e)-12-(pyridin-3-yl)dodeca-5,8,10-trien-2-yl acetate

(2s,5e,8e,10e)-12-(pyridin-3-yl)dodeca-5,8,10-trien-2-yl acetate

C19H25NO2 (299.1885)


   

(1s,2s,4s,6r,7s,10s,11r)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-12-en-6-ol

(1s,2s,4s,6r,7s,10s,11r)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-12-en-6-ol

C20H29NO (299.2249)


   

1-methyl-2-(8-oxononyl)quinolin-4-one

1-methyl-2-(8-oxononyl)quinolin-4-one

C19H25NO2 (299.1885)


   

(2e,7z)-1-(2,3-dihydropyrrol-1-yl)hexadeca-2,7-dien-10-yn-1-one

(2e,7z)-1-(2,3-dihydropyrrol-1-yl)hexadeca-2,7-dien-10-yn-1-one

C20H29NO (299.2249)


   

12-(pyridin-3-yl)dodeca-5,8,10-trien-2-yl acetate

12-(pyridin-3-yl)dodeca-5,8,10-trien-2-yl acetate

C19H25NO2 (299.1885)


   

(1s,2s,4s,6s,7s,10s,11r)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-12-en-6-ol

(1s,2s,4s,6s,7s,10s,11r)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-12-en-6-ol

C20H29NO (299.2249)


   

(2s,3s,6r)-6-(11-hydroxydodecyl)-2-methylpiperidin-3-ol

(2s,3s,6r)-6-(11-hydroxydodecyl)-2-methylpiperidin-3-ol

C18H37NO2 (299.2824)


   

(2r,3r,6r)-6-[(11s)-11-hydroxydodecyl]-2-methylpiperidin-3-ol

(2r,3r,6r)-6-[(11s)-11-hydroxydodecyl]-2-methylpiperidin-3-ol

C18H37NO2 (299.2824)


   

(1s,4r,12r,15r)-15-ethyl-4-hydroxy-1λ⁵,11-diazapentacyclo[13.3.1.0¹,¹².0⁴,¹².0⁵,¹⁰]nonadeca-5,7,9-trien-1-ylium

(1s,4r,12r,15r)-15-ethyl-4-hydroxy-1λ⁵,11-diazapentacyclo[13.3.1.0¹,¹².0⁴,¹².0⁵,¹⁰]nonadeca-5,7,9-trien-1-ylium

[C19H27N2O]+ (299.2123)


   

(1s,2s,4s,6s,7s,10r,11r)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-13-en-6-ol

(1s,2s,4s,6s,7s,10r,11r)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-13-en-6-ol

C20H29NO (299.2249)


   

1-(2,3-dihydropyrrol-1-yl)hexadeca-2,7-dien-10-yn-1-one

1-(2,3-dihydropyrrol-1-yl)hexadeca-2,7-dien-10-yn-1-one

C20H29NO (299.2249)


   

(7z)-1-(pyrrol-1-yl)hexadec-7-en-10-yn-1-one

(7z)-1-(pyrrol-1-yl)hexadec-7-en-10-yn-1-one

C20H29NO (299.2249)


   

(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-4-methylpentanoate

(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-4-methylpentanoate

C16H29NO4 (299.2096)


   

11-(5-hydroxy-6-methylpiperidin-2-yl)undecanoic acid

11-(5-hydroxy-6-methylpiperidin-2-yl)undecanoic acid

C17H33NO3 (299.246)


   

1-(pyrrolidin-1-yl)hexadeca-2,6,8-trien-10-yn-1-one

1-(pyrrolidin-1-yl)hexadeca-2,6,8-trien-10-yn-1-one

C20H29NO (299.2249)


   

hexahydro-1h-pyrrolizin-1-ylmethyl 2-hydroxy-2-(1-hydroxyethyl)-4-methylpentanoate

hexahydro-1h-pyrrolizin-1-ylmethyl 2-hydroxy-2-(1-hydroxyethyl)-4-methylpentanoate

C16H29NO4 (299.2096)


   

(2z,4e)-3-methyl-5-[3-methyl-3-(4-methylpent-3-en-1-yl)oxiran-2-yl]-1-(1h-pyrrol-2-yl)penta-2,4-dien-1-one

(2z,4e)-3-methyl-5-[3-methyl-3-(4-methylpent-3-en-1-yl)oxiran-2-yl]-1-(1h-pyrrol-2-yl)penta-2,4-dien-1-one

C19H25NO2 (299.1885)


   

1-hydroxy-3-methyl-2-[(2e)-non-2-en-1-yl]quinolin-4-one

1-hydroxy-3-methyl-2-[(2e)-non-2-en-1-yl]quinolin-4-one

C19H25NO2 (299.1885)


   

15-ethyl-4-hydroxy-1λ⁵,11-diazapentacyclo[13.3.1.0¹,¹².0⁴,¹².0⁵,¹⁰]nonadeca-5,7,9-trien-1-ylium

15-ethyl-4-hydroxy-1λ⁵,11-diazapentacyclo[13.3.1.0¹,¹².0⁴,¹².0⁵,¹⁰]nonadeca-5,7,9-trien-1-ylium

[C19H27N2O]+ (299.2123)


   

1-hydroxy-3-methyl-2-(non-2-en-1-yl)quinolin-4-one

1-hydroxy-3-methyl-2-(non-2-en-1-yl)quinolin-4-one

C19H25NO2 (299.1885)


   

(2r,3r,6s)-6-[(11s)-11-hydroxydodecyl]-2-methylpiperidin-3-ol

(2r,3r,6s)-6-[(11s)-11-hydroxydodecyl]-2-methylpiperidin-3-ol

C18H37NO2 (299.2824)


   

1-(pyrrol-1-yl)hexadec-7-en-10-yn-1-one

1-(pyrrol-1-yl)hexadec-7-en-10-yn-1-one

C20H29NO (299.2249)


   

hexahydro-1h-pyrrolizin-1-ylmethyl 2-hydroxy-2-(1-hydroxyethyl)-3-methylpentanoate

hexahydro-1h-pyrrolizin-1-ylmethyl 2-hydroxy-2-(1-hydroxyethyl)-3-methylpentanoate

C16H29NO4 (299.2096)